BFRI | Biofrontera Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.1000 - 1.2200
52 Week Range	0.6100 - 9.52
Beta	0.92
Implied Volatility	526.03%
IV Rank	46.01%
Day's Volume	799,846
Average Volume	133,627
Shares Outstanding	5,543,518
Market Cap	6,153,305
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2021-10-29

Valuation
Profitability
Growth
Health
P/E Ratio	-0.41
Forward P/E Ratio	N/A
EPS	-2.74
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	83
Country	USA
Website	BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

BFRI's peers: AKAN, GHSI, SHPH, CPHI, SBFMW, ACOR, LSDI, JUPW, PTPI, EVOK, CPIX, AGRX, PRFX, SXTC, HUGE, EGRX, RGC, PROC, IXHL, IMCC, KALA, RMTI, SCYX, BFRIW

*Chart delayed

Analyzing fundamentals for BFRI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BFRI Fundamentals page.

Watching at BFRI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BFRI Technicals page.